Please select the option that best describes you:
Topics:
Genitourinary Cancers • Medical Oncology • Renal Cell Carcinoma • NCI-CCC Tumor Board Question • Renal tumor • Johns Hopkins • NCI-CCC GU Tumor Board Question
How do you treat patients with newly diagnosed metastatic MiT Family Translocation Renal Cell Carcinoma?
MiT subfamily translocations = TFE3, TFEB, TFC, or MiTF
Answer from: Medical Oncologist at Community Practice
The AREN1721 clinical trial is accepting patients of all ages with unresectable or metastatic TFE/translocation renal cell carcinoma (RCC). The tumors must have either TFE3 expression by immunohistochemical staining or evidence of a TFE3 or TFEB translocation. The three arm trial compares nivolumab,...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Data regarding systemic therapy for patients with metastatic translocation (TFE3 translocation) RCC is limited to observational studies. For first line therapy, I will suggest clinical trial or VEGF-directed therapy such as sunitinib (Malouf et al., PMID 20154303, Choueiri et al., PMID 20665500...